Abstract: Background: Black individuals have higher incidence and mortality rates of prostate cancer than White individuals, and existing literature on treatment sequencing …
Abstract: INTRODUCTION: Treatment of metastatic hormone sensitive prostate cancer (mHSPC) has traditionally included combination therapy of androgen deprivation therapy (ADT) with …
Abstract: Importance: The choice of first line hormonal therapy in metastatic hormone-sensitive prostate cancer (mHSPC) is often based on comorbidities or physician preference due …
Abstract: Introduction: Prostate cancer is the most common cancer in men in the United States with low survival rates once metastasized. Abiraterone is approved for use in …
Abstract: As cancer treatments shift from traditional intravenous chemotherapy to inclusion of oral oncolytics, there is a critical need for structured oral chemotherapy monitoring …
Abstract: BACKGROUND: Abiraterone and enzalutamide are second generation androgen receptor pathway inhibitors (ARPIs) used to treat advanced or metastatic prostate cancer. Without …